[Treatment of blood circulation disorders with a hemoactive-vasoactive drug].
The therapeutic activity of Fludilat in circulatory disorders was evaluated in 9 women and 11 men, with ages between 41 and 75 years. Three suffered atherosclerosis and 17 diabetic vascular disease. Elimination of the symptom was obtained in intermittent claudication in 71 per cent of the patients who suffered it, in 67 per cent in case of feeling of coldness, in 46 per cent in paraesthesias, in 73 per cent in feeling of heaviness and in 6 per cent in trophic changes. In the remaining patients there was a significative reduction in the intensity of the symptoms, except in trophic changes. This result are considered as excellents. The general result of the treatment was satisfactory. There was no significacative change in the blood pressure and no side effects were reported. A better response of the atherosclerotic patients was obtained. We found no influence of age, sex and blood pressure on the results. The study corroborates the efficacy of Fludilat in the treatment of circulatory disorders and its excellent tolerance.
D000328:Adult; D000368:Aged; D001537:Bencyclane / Q000009:adverse effects / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003508:Cycloheptanes / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D003508:Cycloheptanes; D001537:Bencyclane
Tratamiento de los transtornos circulatorios con un farmáco vaso y hemoactivo.